Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | HTR6 | P50406 | 1/20 | 0.60 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.50 |
| ▸ | PDE2A | O00408 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168857 | 0.90 | HTR2B (0.58) | HTR2BHTR6CYP11B2CYP11B1PDE2A | |
| SCHEMBL10252540 | 0.86 | CYP11B2 (0.49) | HTR2BHTR6CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL169041 | 0.84 | PDE2A (0.50) | HTR2BHTR6PDE2ASMN1; SMN2PDE7A | |
| SCHEMBL4448746 | 0.83 | HTR2B (0.67) | HTR2BHTR6CYP11B2CYP11B1PDE2A | |
| SCHEMBL168295 | 0.83 | HTR2B (0.67) | HTR2BHTR6CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL167581 | 0.82 | HTR2B (0.62) | HTR2BHTR6CYP11B2CYP11B1PDE2A | |
| SCHEMBL169511 | 0.80 | HTR2B (0.60) | HTR2BHTR6CYP11B2CYP11B1PDE2A | |
| SCHEMBL168806 | 0.79 | HTR2B (0.59) | HTR2BHTR6CYP11B2CYP11B1PDE2A | |
| SCHEMBL169729 | 0.78 | HTR2B (0.57) | HTR2BHTR6CYP11B2CYP11B1PDE2A | |
| SCHEMBL10248982 | 0.76 | CYP11B2 (0.47) | HTR2BHTR6CYP11B2CYP11B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424856-B1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-8461181-B2 | Fused heterocyclic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8461181-B2 | Fused heterocyclic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8273764-B2 | Fused heterocyclic compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273764-B2 | Fused heterocyclic compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-07-12 | — | — | US | disclosed |
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-07-12 | — | — | US | disclosed |
| EP-2424856-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| WO-2010125985-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | HTR2B 1974/4885HTR6 3015/4885CYP11B2 611/4885 |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | HTR2B 1974/4885HTR6 3015/4885CYP11B2 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.